ORTX
Closed
Orchard Therapeutics Plc
16.7
0.0 (0.00%)
Last Update: 02 Feb 2024 17:30:00
Yesterday: 16.7
Day's Range: 16.7 - 16.7
Send
sign up or login to leave a comment!
When Written:
5.35
Orchard Therapeutics PLC is a biotechnology company that develops gene therapies for rare diseases. The company was founded in 2016 and is headquartered in London, UK, with additional offices in Boston, MA, and Menlo Park, CA. Orchard Therapeutics uses ex vivo gene therapy, which involves modifying a patient's own cells outside the body and then infusing them back into the patient, to treat inherited diseases.
The company's lead product candidate is OTL-101, a gene therapy for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID), also known as "bubble boy" disease. Orchard Therapeutics has also developed gene therapies for other rare diseases, including metachromatic leukodystrophy (MLD), Wiskott-Aldrich syndrome (WAS), and X-linked chronic granulomatous disease (X-CGD).
Orchard Therapeutics has partnerships with a number of academic institutions and pharmaceutical companies, including the University of California, Los Angeles (UCLA), the University of Manchester, and Généthon. The company went public in 2018 and is listed on the Nasdaq Global Select Market under the ticker symbol ORTX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company's lead product candidate is OTL-101, a gene therapy for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID), also known as "bubble boy" disease. Orchard Therapeutics has also developed gene therapies for other rare diseases, including metachromatic leukodystrophy (MLD), Wiskott-Aldrich syndrome (WAS), and X-linked chronic granulomatous disease (X-CGD).
Orchard Therapeutics has partnerships with a number of academic institutions and pharmaceutical companies, including the University of California, Los Angeles (UCLA), the University of Manchester, and Généthon. The company went public in 2018 and is listed on the Nasdaq Global Select Market under the ticker symbol ORTX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!